Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Study of the diagnosis and treatment of renal cell carcinoma using monoclonal antibodies

Thesis/Dissertation ·
OSTI ID:7140230

Among the potential applications of monoclonal antibodies (Mabs) in the diagnosis and treatment of human cancer is the use in the specific detection of cancer sites and the selective destruction of cancer cells. Fetal kidney was used as an immunogen to develop Mab A6H, which is highly reactive to 16/16 renal cell carcinoma (RCC) cell lines and to 16/19 human RCC specimens. RCC xenografts as small as 40 mg have been imaged clearly in radioimmunoscintigraphy studies using A6H labeled with iodine-131. In Mab-targeted radiotherapy studies, 2 doses of 100-150 uCi /sup 131/I-labeled A6H or an /sup 131/ I-labeled A6H-C5H cocktail caused tumor regression or tumor growth arrest in >80% of treated mice, while no such effect was observed in mice treated with /sup 131/I-labeled control Mab or unlabeled A6H. Internal radiation dosimetry, which was calculated by computer analysis of sequential radioimmunoscintigraphy, showed that A6H delivered approximately 35 rad/uCi of the injected dose to RCC xenografts. When the radiation dose to the tumor was <2500 rad, stabilization in tumor growth was not observed. Radiation doses >3000 rad resulted in tumor regression or growth arrest in >85% of mice. A clinical trial using /sup 131/I-labeled A6H in the diagnosis and treatment of RCC is now underway at our institution.

Research Organization:
Minnesota Univ., Minneapolis (USA)
OSTI ID:
7140230
Country of Publication:
United States
Language:
English